A double-blind, randomized phase II study of dicycloplatin plus   paclitaxel versus carboplatin plus paclitaxel as first-line therapy for   patients with advanced non-small-cell lung cancers

doi:10.5114/aoms.2014.44862

CORC > 北京大学 > 化学与分子工程学院

	A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
	Liu, Ke-Jun ; Guan, Zhong-Zhen ; Liang, Ying ; Yang, Xu-Qing ; Peng, Jin ; Huang, He ; Shao, Qing-Xiang ; Wang, Meng-Zhao ; Zhu, Yun-Zhong ; Wu, Chang-Ping ; Wang, Shao-Bin ; Xiong, Jian-Ping ; Bai, Yu-Xian ; Yu, Shi-Ying ; Zhang, Yang ; Hu, Xiao-Hua ; Feng, Ji-Feng ; Wu, Shi-Xiu ; Jiao, Shun-Chang ; Zhou, Cai-Cun ; Wang, Jie ; Wu, Hai-Ying
刊名	archives of medical science
	2014
关键词	dicycloplatin platinum derivative first-line therapy non-small-cell lung cancer (NSCLC) phase II study TRIAL CISPLATIN GEMCITABINE MULTICENTER VINORELBINE COMBINATION PACLITAXEL/CARBOPLATIN NSCLC
DOI	10.5114/aoms.2014.44862
英文摘要	Introduction: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). Material and methods: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m2 (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. The primary endpoint was response rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and adverse events. Results: The response rates for the D + P and C + P arm were 36.44% and 30.51%, respectively (p = 0.33). The median PFS was 5.6 months in the D + P arm and 4.7 months in the C + P arm (p = 0.31). The median OS was 14.9 months for D + P and 12.9 months for C + P (p = 0.37). Adverse events in the two arms were well balanced. The most common grade 3/4 adverse event was hematologic toxicity. Conclusions: Patients treated with D + P had similar response and survival rates to those treated with C + P, and toxicities of both treatments were generally tolerable.; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000341274400012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701 ; Medicine, General & Internal; SCI(E); PubMed; 3; ARTICLE; jiwen0005@126.com; 4; 717-724; 10
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/189070]
专题	化学与分子工程学院
推荐引用方式 GB/T 7714	Liu, Ke-Jun,Guan, Zhong-Zhen,Liang, Ying,et al. A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers[J]. archives of medical science,2014.
APA	Liu, Ke-Jun.,Guan, Zhong-Zhen.,Liang, Ying.,Yang, Xu-Qing.,Peng, Jin.,...&Wu, Hai-Ying.(2014).A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers.archives of medical science.
MLA	Liu, Ke-Jun,et al."A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers".archives of medical science (2014).